Andy joined Rheos as Vice President, Biology and Translational Sciences with over 25 years of drug development experience. Prior to Rheos, Andy spent 13 years in Immunology Discovery at AbbVie where he was involved in the development and launch of RINVOQ, a JAK1 selective inhibitor for the treatment of rheumatoid arthritis. He also led the discovery effort to deliver ABBV-599, a combination of BTK and JAK inhibitors, into clinical development for the treatment of multiple autoimmune diseases. Prior to AbbVie, he spent 15 years at Genetics Institute and Wyeth where he was involved in the discovery and characterization of the cognate ligands for PD-1.
Andy earned his Ph.D. in Pharmacology from Boston University School of Medicine and his B.S. in Biological Sciences from the University of Vermont.